Status:

RECRUITING

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

Lead Sponsor:

University Hospital, Strasbourg, France

Conditions:

Epilepsy in Children

Eligibility:

All Genders

3-17 years

Brief Summary

Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes an...

Eligibility Criteria

Inclusion

  • Minor patient aged 3 months to 17 years
  • 2nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines
  • Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023
  • Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.

Exclusion

  • Patient or parents having expressed their opposition to participating in the study.

Key Trial Info

Start Date :

November 16 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 16 2025

Estimated Enrollment :

151 Patients enrolled

Trial Details

Trial ID

NCT06498362

Start Date

November 16 2023

End Date

May 16 2025

Last Update

July 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Service pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, France, 67091

The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children | DecenTrialz